Contact Us

Veterans Benefits Disability Claims/Denials
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Date of Birth of Person Disabled

   * Date of Disability Occurred

Please Describe Your Disability

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Parker Waichman Representing West Virginia Man in Actos Bladder Cancer Lawsuit

May 1, 2012 | Parker Waichman LLP

Parker Waichman LLP has filed another Actos bladder cancer lawsuit, this time on behalf of a West Virginia man who developed the disease after taking Actos for several years.  The lawsuit alleges that Defendants, Takeda Pharmaceuticals and Eli Lilly, promoted Actos as a safe and effective treatment for type II diabetes, even though they knew or should have known that taking Actos for longer than 12 months increased the risk of bladder cancer.

This latest Actos bladder cancer lawsuit was filed by Parker Waichman in the Western District of Louisiana as part of In Re: Actos (Pioglitazone) Products Liability Litigation (MDL 2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, has been appointed to the Plaintiffs' Steering Committee in the Actos Litigation.

According to the complaint, the Plaintiff developed bladder cancer several years after he was prescribed and began taking Actos in 2005.  The lawsuit alleges that because of his use of Actos, the Plaintiff sustained severe, permanent and life-threatening personal injuries, pain, suffering, emotional distress, and lifelong fear of premature death. It further alleges that because of his use of Actos, the Plaintiff will require continued lifelong monitoring, treatment and medications.

This past June, the U.S. Food & Drug Administration (FDA) issued a safety communication stating that use of Actos for more than one year may be associated with an increased risk of bladder cancer. The June safety communication was a follow-up to one the agency issued in September 2010 after preliminary data from a study conducted by Kaiser Permanente demonstrated that the risk of bladder cancer rises with increasing dose and duration of Actos use, reaching statistical significance after 24 months. Bladder cancer concerns also caused regulators in France and Germany to suspend sales of Actos in those countries over the summer. Takeda officially recalled Actos from the French market in July.

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo